CN101254171A - 含有小分子干扰核糖核酸的喷雾剂 - Google Patents
含有小分子干扰核糖核酸的喷雾剂 Download PDFInfo
- Publication number
- CN101254171A CN101254171A CNA2007101110136A CN200710111013A CN101254171A CN 101254171 A CN101254171 A CN 101254171A CN A2007101110136 A CNA2007101110136 A CN A2007101110136A CN 200710111013 A CN200710111013 A CN 200710111013A CN 101254171 A CN101254171 A CN 101254171A
- Authority
- CN
- China
- Prior art keywords
- sirna
- shrna
- target
- microrna
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003384 small molecules Chemical class 0.000 title claims abstract description 45
- 229920002477 rna polymer Polymers 0.000 title claims description 48
- 239000007921 spray Substances 0.000 title claims description 42
- 241000700605 Viruses Species 0.000 claims abstract description 47
- 239000002502 liposome Substances 0.000 claims abstract description 24
- 230000003612 virological effect Effects 0.000 claims abstract description 15
- 108091036078 conserved sequence Proteins 0.000 claims abstract description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 46
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 34
- 241000712461 unidentified influenza virus Species 0.000 claims description 24
- 108700011259 MicroRNAs Proteins 0.000 claims description 10
- 239000002679 microRNA Substances 0.000 claims description 10
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 238000012772 sequence design Methods 0.000 claims description 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 26
- 208000036142 Viral infection Diseases 0.000 abstract description 13
- 230000009385 viral infection Effects 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 230000002452 interceptive effect Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000002269 spontaneous effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 238000005507 spraying Methods 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 230000007482 viral spreading Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 81
- 230000009368 gene silencing by RNA Effects 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 27
- 238000000034 method Methods 0.000 description 26
- 238000001890 transfection Methods 0.000 description 26
- 238000013461 design Methods 0.000 description 25
- 108020004999 messenger RNA Proteins 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 239000013642 negative control Substances 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 14
- 238000011160 research Methods 0.000 description 11
- 230000030279 gene silencing Effects 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000012226 gene silencing method Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 241001500351 Influenzavirus A Species 0.000 description 5
- 241001500343 Influenzavirus C Species 0.000 description 5
- 101710172711 Structural protein Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000011007 phosphoric acid Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- VQSJAWPFQCXIOB-VODLGYORSA-N 2,3-dihydroxypropyl [(1r,2r,3s,4r,5r,6s)-2,3,6-trihydroxy-4,5-diphosphonooxycyclohexyl] hydrogen phosphate Chemical compound OCC(O)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O VQSJAWPFQCXIOB-VODLGYORSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- 150000003906 phosphoinositides Chemical class 0.000 description 4
- 150000003016 phosphoric acids Chemical class 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010014477 Foot-and-mouth disease virus virus-infection-associated antigen Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241001500350 Influenzavirus B Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 241000726445 Viroids Species 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000009305 pseudorabies Diseases 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101100232687 Drosophila melanogaster eIF4A gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710091919 Eukaryotic translation initiation factor 4G Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 101150076514 NS gene Proteins 0.000 description 1
- 101710188642 Non-structural protein 3b Proteins 0.000 description 1
- 101710188643 Non-structural protein 3c Proteins 0.000 description 1
- 101710188639 Non-structural protein 3d Proteins 0.000 description 1
- 101800000440 Non-structural protein NS3A Proteins 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 101150105115 PA gene Proteins 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000012231 antisense RNA technique Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 108700029658 influenza virus NS Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101110136A CN101254171B (zh) | 2006-06-13 | 2007-06-13 | 含有小分子干扰核糖核酸的喷雾剂 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610087225 | 2006-06-13 | ||
CN200610087225.0 | 2006-06-13 | ||
CN2007101110136A CN101254171B (zh) | 2006-06-13 | 2007-06-13 | 含有小分子干扰核糖核酸的喷雾剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101254171A true CN101254171A (zh) | 2008-09-03 |
CN101254171B CN101254171B (zh) | 2011-09-21 |
Family
ID=39889499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101110136A Expired - Fee Related CN101254171B (zh) | 2006-06-13 | 2007-06-13 | 含有小分子干扰核糖核酸的喷雾剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101254171B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103966212A (zh) * | 2013-02-06 | 2014-08-06 | 霍晋 | A型流感病毒NP基因有干扰作用的siRNA序列的设计及应用 |
CN104419702A (zh) * | 2013-09-04 | 2015-03-18 | 北京中康万达医药科技有限公司 | 一种基于生物信息学筛选siRNA的方法 |
CN107746857A (zh) * | 2017-08-07 | 2018-03-02 | 中国农业大学 | 一种抑制基因表达的rna干扰方法 |
CN107778364A (zh) * | 2017-08-07 | 2018-03-09 | 中国农业大学 | 一种影响羊早期胚胎发育的nlrp7基因及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100345965C (zh) * | 2005-08-04 | 2007-10-31 | 复旦大学 | 能抑制口蹄疫病毒复制与感染的siRNA及其制备方法 |
CN100365123C (zh) * | 2005-12-30 | 2008-01-30 | 中国疾病预防控制中心病毒病预防控制所 | 针对乙型流感病毒膜蛋白基因的siRNA序列及其应用 |
-
2007
- 2007-06-13 CN CN2007101110136A patent/CN101254171B/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103966212A (zh) * | 2013-02-06 | 2014-08-06 | 霍晋 | A型流感病毒NP基因有干扰作用的siRNA序列的设计及应用 |
CN104419702A (zh) * | 2013-09-04 | 2015-03-18 | 北京中康万达医药科技有限公司 | 一种基于生物信息学筛选siRNA的方法 |
CN107746857A (zh) * | 2017-08-07 | 2018-03-02 | 中国农业大学 | 一种抑制基因表达的rna干扰方法 |
CN107778364A (zh) * | 2017-08-07 | 2018-03-09 | 中国农业大学 | 一种影响羊早期胚胎发育的nlrp7基因及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101254171B (zh) | 2011-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Morales et al. | SARS-CoV-encoded small RNAs contribute to infection-associated lung pathology | |
EP2633049B1 (en) | Methods and compositions to protect aquatic invertebrates from disease | |
Wilton et al. | Effect of formaldehyde inactivation on poliovirus | |
Ababneh et al. | Presence of infectious bronchitis virus strain CK/CH/LDL/97I in the Middle East | |
US20150157703A1 (en) | Method of rapidly producing improved vaccines for animals | |
Zheng et al. | Engineering foot-and-mouth disease viruses with improved growth properties for vaccine development | |
CN101184839A (zh) | 用于呼吸道病毒感染的RNAi治疗 | |
Liang et al. | Selection of an aptamer against rabies virus: a new class of molecules with antiviral activity | |
CN102757942A (zh) | A型口蹄疫重组疫苗株及其制备方法和应用 | |
CN101254171B (zh) | 含有小分子干扰核糖核酸的喷雾剂 | |
Servan de Almeida et al. | Control of ruminant morbillivirus replication by small interfering RNA | |
Li et al. | In vitro inhibition of CSFV replication by retroviral vector-mediated RNA interference | |
CN101880677B (zh) | 针对2009新甲型流感病毒多聚酶基因和核蛋白基因的siRNA序列及其应用 | |
Tan et al. | Inhibition of enterovirus 71 infection by antisense octaguanidinium dendrimer-conjugated morpholino oligomers | |
Meng et al. | RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production | |
Lv et al. | Transient inhibition of foot-and-mouth disease virus replication by siRNAs silencing VP1 protein coding region | |
Sui et al. | Integrated miRNA and mRNA expression profiles reveal differentially expressed miR-222a as an antiviral factor against duck hepatitis A virus type 1 infection | |
He et al. | Attenuation of a Highly Pathogenic Porcine Deltacoronavirus Strain CZ2020 by a Serial Passage In Vitro | |
CN102337263B (zh) | 抑制肠道病毒71型基因表达的siRNA及组合物和应用 | |
WO2015085904A1 (zh) | 禽流感病毒miRNA及其鉴定、检测和应用 | |
Chen et al. | Construction and characterization of an improved DNA-launched infectious clone of duck hepatitis a virus type 1 | |
WO2015085903A1 (zh) | 体内感染微生物、寄生微生物、共生微生物的非编码性rna及其鉴定和应用 | |
CN105602989B (zh) | 一种重组载体及其在制备或筛选抗流感药物中的应用 | |
CN101386860A (zh) | 一种构建脑心肌炎病毒感染性克隆的方法 | |
WO2013066665A1 (en) | Method of rapidly producing improved vaccines for animals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right |
Effective date of registration: 20150318 Granted publication date: 20110921 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20150918 Granted publication date: 20110921 |
|
PP01 | Preservation of patent right |
Effective date of registration: 20150918 Granted publication date: 20110921 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20160318 Granted publication date: 20110921 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PP01 | Preservation of patent right |
Effective date of registration: 20160318 Granted publication date: 20110921 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20160918 Granted publication date: 20110921 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110921 Termination date: 20160613 |